{
  "title": "LAI Intelligence Weekly P1 Test – 2025-12-12",
  "intro": "This week highlights significant advances in long-acting injectable technologies with a major partnership and FDA approval in the schizophrenia treatment space.",
  "tldr": [
    "Nanexa partners with Moderna to develop long-acting injectable formulations using PharmaShell® technology",
    "Teva's UZEDY® receives FDA approval as extended-release injectable treatment for schizophrenia"
  ],
  "sections": [
    {
      "section_title": "Top Signals – LAI Ecosystem",
      "section_intro": "Key developments this week include a strategic technology partnership and a regulatory milestone for schizophrenia treatment.",
      "items": [
        {
          "title": "Nanexa and Moderna Announce PharmaShell® LAI Technology Partnership",
          "rewritten_summary": "Nanexa AB has entered into a partnership with Moderna to develop long-acting injectable formulations utilizing Nanexa's proprietary PharmaShell® technology platform. This collaboration aims to extend the duration of therapeutic effect for Moderna's pharmaceutical products.",
          "url": "#"
        },
        {
          "title": "UZEDY® (aripiprazole) Extended-Release Injectable Receives FDA Approval",
          "rewritten_summary": "Teva Pharmaceuticals announced FDA approval of UZEDY®, an extended-release injectable formulation of aripiprazole for the treatment of schizophrenia. This approval provides patients with a new long-acting treatment option in the antipsychotic medication category.",
          "url": "#"
        }
      ]
    },
    {
      "section_title": "Partnerships & Deals",
      "section_intro": "Strategic collaborations are advancing the development of next-generation long-acting injectable technologies.",
      "items": [
        {
          "title": "Nanexa and Moderna Announce PharmaShell® LAI Technology Partnership",
          "rewritten_summary": "Nanexa AB has entered into a partnership with Moderna to develop long-acting injectable formulations utilizing Nanexa's proprietary PharmaShell® technology platform. This collaboration aims to extend the duration of therapeutic effect for Moderna's pharmaceutical products.",
          "url": "#"
        }
      ]
    }
  ]
}